All In Biotech

Drug Trial Radar · NCT07158151

A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of RSS0393 Ointment in Adults With Mild to Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Sep 25, 2025

Primary completion

Apr 10, 2026

Study completion Apr 10, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is ongoing to explore the efficacy and safety of different strengths of RSS0393 ointment in adults with atopic dermatitis

Conditions

  • Atopic Dermatitis of Adults

Interventions

  • RSS0393 ointmentDrug

    RSS0393 ointment 0.05%

  • RSS0393 ointmentDrug

    RSS0393 ointment 0.01%

  • RSS0393 ointmentDrug

    RSS0393 ointment 0.03%

  • RSS0393 ointmentDrug

    RSS0393 ointment placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with vIGA-AD successTime frame: Baseline, week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.